Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS

Executive Summary

The partial clinical hold placed on a combination trial of AstraZeneca’s PD-L1 inhibitor durvalumab and CTLA-4 inhibitor tremelimumab could be a portent of problems for Bristol-Myers Squibb’s PD-1/CTLA-4 combination trials – or it could be related to the head and neck cancer setting.

Advertisement

Related Content

Pfizer’s Avelumab Poised For Speedy Review By FDA
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
PD-1 Deep Dive: Lung Cancer Market Braced For Change
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Bristol Still Rules Immuno-Oncology, But For How Long?
Bristol Still Rules Immuno-Oncology, But For How Long?
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
AstraZeneca’s Oncology Strategy: It’s All About The End Results

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel